Cumberland Pharmaceuticals Inc (CPIX)

NASDAQ
2.590
+0.120(+4.86%)
  • वॉल्यूम:
    7,216
  • दिन की रेंज:
    2.450 - 2.670
  • 52 सप्ताह रेंज:
    1.890 - 7.510

CPIX समीक्षा

पिछला बंद
2.47
दिन की रेंज
2.45-2.67
आय
37.87M
खुला
2.49
52 सप्ताह रेंज
1.89-7.51
ईपीएस
-0.516
वॉल्यूम
7,216
मार्केट कैप
37.97M
लाभांश (यील्ड)
N/A
(N/A)
औसत वॉल्यूम (3एम)
9,292
पी/ई अनुपात
-4.50
बीटा
0.319
1- वर्ष बदलाव
-9.85%
बकाया शेयर
14,661,937
अगली कमाई तिथि
14 नव॰ 2022
Cumberland पर आपकी भावना क्या है?
या
अभी बाज़ार बंद हैं। वोटिंग बाजार का समय के दौरान खुली है।

Cumberland Pharmaceuticals Inc विश्लेषण

Cumberland Pharmaceuticals Inc कंपनी प्रोफाइल

Cumberland Pharmaceuticals Inc कंपनी प्रोफाइल

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

और पढ़ें

तकनीकी सारांश

प्रकार
5 मिनट
15 मिनट
प्रति घंटा
दैनिक
मासिक
मूविंग एवरेजबेचनाबेचनाबेचनामजबूत खरीदबेचना
तकनीकी संकेतकमजबूत विक्रयमजबूत विक्रयमजबूत विक्रयमजबूत खरीदमजबूत विक्रय
सारांशमजबूत विक्रयमजबूत विक्रयमजबूत विक्रयमजबूत खरीदमजबूत विक्रय